Nisa Investment Advisors
ABUS icon

Nisa Investment Advisors’s Arbutus Biopharma ABUS Stock Holding History

Nisa Investment Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15K Buy
3,117
+481
+18% +$2.11K ﹤0.01% 2354
2026
Q1 		$11.9K Buy
2,636
+1
+0% +$4 ﹤0.01% 2182
2025
Q4 		$12.7K Hold
2,635
– – ﹤0.01% 2126
2025
Q3 		$12K Hold
2,635
– – ﹤0.01% 2214
2025
Q2 		$8.14K Sell
2,635
-1,735
-40% -$5.76K ﹤0.01% 2346
2025
Q1 		$15.3K Buy
4,370
+203
+5% +$677 ﹤0.01% 1991
2024
Q4 		$13.6K Sell
4,167
-250
-6% -$920 ﹤0.01% 2052
2024
Q3 		$17K Buy
4,417
+250
+6% +$959 ﹤0.01% 1960
2024
Q2 		$12.9K Buy
4,167
+342
+9% +$1.03K ﹤0.01% 2073
2024
Q1 		$9.87K Hold
3,825
– – ﹤0.01% 2035
2023
Q4 		$9.56K Buy
3,825
+75
+2% +$147 ﹤0.01% 2052
2023
Q3 		$7.61K Sell
3,750
-52
-1% -$109 ﹤0.01% 2227
2023
Q2 		$8.74K Hold
3,802
– – ﹤0.01% 2279
2023
Q1 		$12K Hold
3,802
– – ﹤0.01% 2126
2022
Q4 		$9K Buy
3,802
+52
+1% +$124 ﹤0.01% 2217
2022
Q3 		$9K Sell
3,750
-2,400
-39% -$5.65K ﹤0.01% 2199
2022
Q2 		$17K Buy
6,150
+3,450
+128% +$8.83K ﹤0.01% 2081
2022
Q1 		$8K Buy
+2,700
New +$8.27K ﹤0.01% 2236

Other funds holding ABUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return
LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return
CCA
Carrera Capital Advisors Troy, Michigan $675M AUM 17.92% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Nisa Investment Advisors's ABUS Position: Q2 2026 in Review

Nisa Investment Advisors increased its Arbutus Biopharma (ABUS) stake by 18% in Q2 2026, buying an estimated $2.11K and bringing the position to 3,117 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #2354.

Nisa Investment Advisors first reported a position in ABUS in Q1 2022 and has held it in 18 quarters since. The position peaked at $17K in Q3 2024. 58 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Nisa Investment Advisors held 3,117 shares of Arbutus Biopharma worth $15K as of Q2 2026.
  • Nisa Investment Advisors bought 481 Arbutus Biopharma shares in Q2 2026, an estimated $2.11K.
  • Arbutus Biopharma made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2354 holding.
  • Nisa Investment Advisors first reported a position in Arbutus Biopharma in Q1 2022 and has held it in 18 quarters since.
  • Nisa Investment Advisors's Arbutus Biopharma position peaked at $17K in Q3 2024.
  • 58 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.